Axys partner Bayer discontinues asthma compound

Based on toxicology data, Bayer (DAX:BAYG) will discontinue development of BAY 44-3428, an oral small molecule tryptase inhibitor co-developed by AXPH and BAYG under a 1994 agreement. Last month, AXPH...